E
Ellen K. Ritchie
Researcher at Cornell University
Publications - 206
Citations - 5919
Ellen K. Ritchie is an academic researcher from Cornell University. The author has contributed to research in topics: Myeloid leukemia & Cytarabine. The author has an hindex of 31, co-authored 186 publications receiving 4615 citations. Previous affiliations of Ellen K. Ritchie include NewYork–Presbyterian Hospital & Columbia University.
Papers
More filters
Journal ArticleDOI
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet,Geoffrey L. Uy,Jorge E. Cortes,Laura F. Newell,Tara L. Lin,Ellen K. Ritchie,Robert K. Stuart,Stephen A. Strickland,Donna E. Hogge,Scott R. Solomon,Richard Stone,Dale L. Bixby,Jonathan E. Kolitz,Gary J. Schiller,Matthew J. Wieduwilt,Daniel H. Ryan,Antje Hoering,Kamalika Banerjee,Michael Chiarella,Arthur C. Louie,Bruno C. Medeiros +20 more
TL;DR: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML, and improved outcomes were observed across age-groups and AML subtypes.
Journal ArticleDOI
Somatic mutations precede acute myeloid leukemia years before diagnosis.
Pinkal Desai,Nuria Mencia-Trinchant,Oleksandr Savenkov,Michael S. Simon,Gloria Cheang,Sangmin Lee,Michael B. Samuel,Ellen K. Ritchie,Monica L. Guzman,Karla V. Ballman,Gail J. Roboz,Duane C. Hassane +11 more
TL;DR: The presence of detectable mutations years before diagnosis suggests that there is a period of latency that precedes AML during which early detection, monitoring and interventional studies should be considered.
Journal ArticleDOI
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge E. Cortes,Philippe Rousselot,Dong-Wook Kim,Ellen K. Ritchie,Nelson Hamerschlak,Steven Coutre,Andreas Hochhaus,François Guilhot,Giuseppe Saglio,Jane F. Apperley,Oliver G. Ottmann,Neil P. Shah,Philipp Erben,Susan Branford,Prasheen Agarwal,Ashwin Gollerkeri,Michele Baccarani +16 more
TL;DR: Dasatinib is highly active and produces hematologic and cytogenetic responses in a significant number of patients with imatinib-resistant or -intolerant MBC- and LBC-CML.
Journal ArticleDOI
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl,Jessica K. Altman,Jorge E. Cortes,Catherine C. Smith,Mark R. Litzow,Maria R. Baer,David F. Claxton,Harry P. Erba,Stan Gill,Stuart L. Goldberg,Joseph G. Jurcic,Richard A. Larson,Chaofeng Liu,Ellen K. Ritchie,Gary J. Schiller,Alexander I. Spira,Stephen A. Strickland,Raoul Tibes,Raoul Tibes,Celalettin Ustun,Eunice S. Wang,Robert K. Stuart,Christoph Röllig,Andreas Neubauer,Giovanni Martinelli,Erkut Bahceci,Mark J. Levis +26 more
TL;DR: Gilteritinib was well tolerated in this heavily pretreated population; Grade 3 diarrhea and hepatic transaminase elevation limited dosing above 300 mg/d; response rate was improved in FLT3mut+ patients at doses ≥80mg/d.
Journal ArticleDOI
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Giovanni Martinelli,Nicolas Boissel,Patrice Chevallier,Oliver G. Ottmann,Nicola Gökbuget,Max S. Topp,Adele K. Fielding,Alessandro Rambaldi,Ellen K. Ritchie,Cristina Papayannidis,Lulu Ren Sterling,Jonathan Benjamin,Anthony S. Stein +12 more
TL;DR: Single-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ ALL who had relapsed or were refractory to TKIs and intolerant or refractor to imatinib.